GlassScriptPhysician profile
Chioma Madu
NPI 1447744925
$1,790.68
in general payments reported to CMS, 2019-2025
24 companies · $682 in 2025
The $682 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $160 · 2023: $480 · 2024: $469 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,630.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $324.36 | 2023-2025 | Renal - Chronic, Hillrom - Carnation Ambulatory Monitor |
| Ani Pharmaceuticals, INC. | $217.05 | 2024-2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $144.56 | 2023-2024 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $135.36 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $92.71 | 2024-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $90.81 | 2024-2025 | Veltassa |
| Amgen INC. | $85.22 | 2024-2025 | Tavneos |
| Akebia Therapeutics INC | $66.84 | 2024-2025 | Vafseo, Auryxia |
| Bayer Healthcare Pharmaceuticals INC. | $63.46 | 2023-2024 | |
| Novo Nordisk INC | $51.29 | 2025 | Wegovy, Saxenda, Ozempic |
| Mallinckrodt Hospital Products INC. | $48.75 | 2024-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $41.32 | 2023-2025 | Ultomiris |
| Medtronic, INC. | $38.91 | 2025 | Symplicity G3 |
| Travere Therapeutics, INC. | $35.32 | 2025 | |
| Aurinia Pharma U.S., INC. | $29.33 | 2025 | Lupkynis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $28.30 | 2024-2025 | Mounjaro, Zepbound |
| Insulet Corporation | $24.11 | 2025 | Omnipod |
| Exact Sciences Corporation | $19.19 | 2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $16.29 | 2025 | Jynarque |
| Xeris Pharmaceuticals, INC. | $16.18 | 2024 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.51 | 2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $15.30 | 2025 | Gattex |
| Kyowa Kirin, INC. | $15.21 | 2023 | Crysvita |
| Ardelyx, INC. | $14.97 | 2025 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chioma Madu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.